ArticleCell death & disease2015

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

J D Leverson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.